Redotil

Quick links to important sections

Redotil

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Redotil

Property Description
Active ingredient Racecadotril
Form Capsules, Granules (for oral suspension)
Pharmacological Class Antidiarrheal Agent, Enkephalinase Inhibitor
Common Use Relief from acute watery diarrhea
Origin Synthetic Prodrug

Defining Redotil: Classification and Active Composition

Redotil is the trade name for the medication containing the active compound Racecadotril, which is classified primarily as an Antidiarrheal Agent and, more specifically, as an Enkephalinase Inhibitor. This compound is a synthetic prodrug that acts only after the body metabolizes it into its active moiety, Thiorphan. The medication’s fundamental identity is defined by this single active ingredient, which represents a modern, targeted approach to managing diarrhea.

The mechanism's role in providing relief is established. The medicine is specifically formulated as a single-ingredient product, focusing entirely on the efficacy of Racecadotril to manage the symptoms of acute, watery diarrhea.


Targeted Purpose and Available Formats

The general therapeutic purpose of Redotil is to mitigate the excessive loss of fluid and electrolytes from the intestinal lining, thereby providing symptomatic relief during an acute diarrheal episode. This action helps the body regain control over its fluid balance. Its oral administration is tailored across age groups: capsules are typically used for adults, while fine granules packaged in sachets are easily suspended in liquid, ensuring practical administration for infants and young children, a key differentiating factor in its market positioning.


How Racecadotril Differs from Motility Reducers

Racecadotril is fundamentally an antisecretory agent, directly reducing the abnormal secretion of fluid into the intestines, addressing the primary cause of watery stool. This mechanism is crucial as it distinguishes Redotil from other common antidiarrheal medicines, such as motility reducers, that primarily work by slowing the muscular movements of the bowel. By avoiding interference with intestinal transit time, Racecadotril helps decrease the volume of fluid loss while allowing the body to maintain normal gut function.

What side effects are possible with Redotil?

Possible Side Effects and Safety Information

The safety profile of Redotil (Racecadotril) is classified based on official regulatory documents that detail adverse reactions according to the physiological system affected and their reported frequency. The official documentation identifies side effects ranging from common occurrences to rare, serious reactions.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped using standard regulatory frequency definitions:

  • Common (may affect up to 1 in 10 people): Headache (Nervous system disorders).
  • Uncommon (may affect up to 1 in 100 people): Rash and Erythema (Skin and subcutaneous tissue disorders).

Reactions categorized as Frequency not known are those identified through post-marketing experience for which the incidence rate cannot be accurately estimated. These include various skin and immune disorders.


Serious Adverse Reactions and Safety Constraints

The most clinically significant safety concerns are related to hypersensitivity reactions. Officially documented serious adverse reactions include Angioedema (a severe swelling reaction), Anaphylactic shock, and Severe Cutaneous Adverse Reactions (SCARs), such as Drug reaction with eosinophilia and systemic symptoms (DRESS). Treatment must be immediately discontinued if any severe cutaneous or hypersensitivity reaction occurs.

Safety constraints restrict the use of Redotil in specific contexts. The medication is not recommended for infants under three months of age, or in patients with signs of acute dysentery (such as bloody or purulent stools and fever). Due to limited available data, caution is advised for use in individuals with severe renal or hepatic impairment. The drug is also not recommended during pregnancy or breastfeeding.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented information regarding overdose of Redotil (Racecadotril) as described in government regulatory sources.


Overdose Scope: Documented Manifestations and Actions

Area of Concern Regulatory Statement
Documented Overdose Presentations: Acute overdose, even at doses approximately 20 times the therapeutic dose (over 2 g in adults), has been reported as occurring without the description of adverse events in regulatory documents.
Physiological Systems Affected: Official prescribing information does not document specific severe or life-threatening adverse effects on physiological systems directly attributable to acute overdose.
Emergency-Response Management: Management is restricted to symptomatic treatment and supportive measures as clinically indicated.
Antidote Status: Regulatory labeling confirms that no specific antidote is known for Racecadotril overdose.

Official Regulatory Requirements

Official documents mandate that patients or caregivers must seek immediate medical advice or attention in the event of a suspected or accidental overdose, irrespective of the initial clinical presentation. This requirement stands because no specific antidote exists, and management depends entirely on supportive care.


Overdose-Context Constraints

The available regulatory overdose profile does not delineate specific, documented differences in severity or management for pediatric, elderly, or renally/hepatically impaired patient populations.

Therapeutic Uses of Redotil

Quick Facts: Uses of Redotil

  • Acute Diarrhea: Used for the symptomatic treatment of sudden-onset, short-term diarrhea in adults and children over 3 months of age.
  • Fluid Management: Helps reduce excessive loss of water and electrolytes in the intestine.
  • Adjunctive Therapy: Is consistently used as a complementary treatment alongside oral rehydration solutions (ORS).

Understanding the Therapeutic Use of Redotil

Redotil is medically indicated for the symptomatic treatment of acute diarrhea in adults and in infants and children over 3 months of age. Acute diarrhea is defined as the sudden onset of three or more loose stools per day, lasting less than 14 days. This medication functions by acting directly in the intestine to help reduce the excessive secretion of water and electrolytes into the gut lumen. This anti-secretory action helps to reduce stool volume and frequency.

The medication is consistently prescribed as an adjunctive therapy, meaning it is always used alongside oral rehydration solutions to ensure adequate replacement of lost fluids and electrolytes. The main therapeutic benefit is its role in decreasing the symptoms and duration of acute diarrhea by addressing intestinal hypersecretion without altering intestinal motility (bowel movement time), a key feature that helps to avoid rebound constipation after resolution of the acute episode.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Redotil — Official Regulatory Information

Eligibility Status Key Population Entities
Allowed Use Adults and children ge 3 months of age for acute diarrhea.
Contraindications Hypersensitivity, specific hereditary disorders, history of ACE inhibitor-induced angioedema.
Restrictions Severe renal impairment, hepatic impairment, pregnancy, lactation, infants <3 months.

Populations for whom use is allowed (as stated in label):

  • Adults and children ge 3 months of age with acute diarrhea.

Populations for whom use is contraindicated:

  • Patients with a confirmed history of hypersensitivity to racecadotril or excipients.
  • Patients with hereditary fructose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption due to excipients in the formulation.
  • Individuals with a history of angioedema reported with ACE inhibitors.

Eligibility-related restrictions:

  • Use is not recommended for infants <3 months of age because safety has not been established.
  • Use is not recommended or advised with caution in cases of severe hepatic or renal impairment due to limited data.
  • The medication should not be administered during pregnancy or lactation, or in the presence of diarrhea with bloody/purulent stools and high fever.

Connection to the overall eligibility profile: Regulatory documents establish the official eligibility profile by defining groups permitted standard use against a set of strictly prohibited and restricted populations. These mandates formally exclude individuals based on specific conditions, physiological status, and insufficient safety data, limiting the approved scope exclusively to the acute, uncomplicated setting in eligible patient demographics.

What should I know about interactions with other medicines?

The regulatory documentation for Racecadotril (Redotil) defines a specific pharmacodynamic interaction and confirms a low potential for pharmacokinetic interactions with other substances.

Category Official Regulatory Statement
Medicinal Product Categories Angiotensin-Converting Enzyme (ACE) Inhibitors.
Specific Interacting Medicines Loperamide, Nifuroxazide.

The most critical interaction constraint is related to ACE Inhibitors (such as Lisinopril or Ramipril). The co-administration of Racecadotril with this class of medicine increases the risk of bradykinin-mediated angioedema. Consequently, co-treatment is prohibited for any patient who has a prior history of angioedema associated with ACE Inhibitor use. This constitutes a mandatory, interaction-related restriction documented in official labeling.

Conversely, the compound has a confirmed low potential for affecting the exposure of many co-administered medicines. The regulatory profile states that Racecadotril and its metabolites do not induce major CYP or UGT enzymes, indicating a low risk for metabolic drug-drug interactions. In clinical studies, co-treatment with antidiarrheal agents like Loperamide or Nifuroxazide does not modify the exposure (plasma levels) of Racecadotril. Limited clinical data exist for patients with hepatic or renal impairment, leading to an official regulatory caution regarding potential altered clearance and exposure in these specific populations.

Mechanism of Action

How Redotil Works

Redotil's mechanism is a targeted antisecretory process that modulates net fluid transport across the intestinal epithelium without affecting intestinal muscle tone or motility.


Enzyme Inhibition and Endogenous Enkephalin Protection

The drug's action is initiated by its inactive precursor, Racecadotril, which is metabolized into the active molecule, Thiorphan. Thiorphan acts as a competitive inhibitor of the enzyme Neutral Endopeptidase (NEP), a peptidase located on the intestinal lining. This inhibition is the core mechanistic step, preventing the degradation of endogenous fluid-regulating peptides, the endogenous enkephalins. By allowing enkephalins to persist, the mechanism prolongs the presence of enkephalins to allow greater receptor activation on the gut surface.


Selective Modulation of Intestinal Hypersecretion

The increased local concentration of enkephalins activates specific delta-opioid receptors on the epithelial cells. This activation triggers an internal cascade that reduces the concentration of the signaling molecule cAMP inside the cell. This mechanistic shift limits the over-activity of ion channels responsible for the active secretion of chloride ions ( Cl^-) and, consequently, water into the intestinal lumen. The resulting physiological effect is a precise reduction in water and ion secretion without modulating intestinal peristalsis or transit time.

Dosage and Administration Information

Administration and Dosing of Redotil

Redotil (Racecadotril) is used according to specific, standardized instructions. Adherence to these guidelines ensures proper administration and duration of use for the symptomatic treatment of acute diarrhea.


Routes and Available Forms

Redotil is administered exclusively via the oral route. It is available in two main forms tailored for different age groups:

  • Hard Capsules (100 mg): Typically used for adults.
  • Granules for Oral Suspension (10 mg and 30 mg sachets): Used for infants and children over 3 months of age.

Standard Dosing and Usage Constraints

The standard dosage regimen is three times daily (TID) and is prescribed as an adjunctive treatment alongside Oral Rehydration Solutions (ORS).

Population Initial Dose Maintenance Dose and Frequency Treatment Duration
Adults One 100 mg capsule One 100 mg capsule three times daily (preferably before meals) Must not exceed 7 days
Pediatric Standard dose is given immediately 1.5 mg/kg body weight three times daily (via granules) Must not exceed 7 days

Key Administration Rules:

  • Preparation: Pediatric granules must be mixed with food or dispersed immediately in water/liquid and administered right away.
  • Duration: Treatment should be continued until the patient passes two normal stools, but the total course must not exceed seven days.
  • Age Restriction: The medication is not recommended for infants less than 3 months old due to insufficient clinical data.

Recent Clinical Evidence

Research evidence / Overview of studies for Redotil

Evidence for Symptomatic Treatment of Acute Watery Diarrhea

The core understanding of the research structure for Redotil comes primarily from short-term randomized controlled trials (RCTs). These studies were designed to examine Redotil, which contains Racecadotril, as an adjunctive therapy used alongside standard care, specifically Oral Rehydration Solutions (ORS). Research focused on outcomes related to episodic or acute changes, such as the duration of the diarrheal episode and the total volume and frequency of diarrheal stools monitored over short periods (e.g., 48 or 72 hours).

Some trials reported findings related to time-to-recovery in the groups receiving Redotil compared to those receiving only a placebo or ORS. The evidence base is considered heterogeneous, meaning findings have varied across studies due to differences in populations or trial designs. Furthermore, studies on acute diarrhea that persists beyond the typical few days addressed in the clinical trials remain limited.


Evidence in Different Age Groups: Children and Adults

Studies on Redotil have been conducted across the spectrum of ages, focusing on both pediatric cohorts (infants and children ge 3 months of age) and adult cohorts. These studies often explored outcomes reflecting daily functioning or activity level alongside the measured changes in stool volume. However, the findings apply only to the specific populations studied, and data are limited for individuals with severe dehydration requiring intravenous fluids or those with bloody stool.


Long-Term Studies and Extended Follow-up

Since acute diarrhea is a short-lived condition, the pivotal studies monitored participants for very short durations, with primary outcomes assessed within 48 to 72 hours. As a result, research on long-term outcomes remains insufficient. Follow-up durations were limited, and research does not consistently track patterns related to extended symptom control or potential for relapse after the short treatment course is complete.


What Remains Uncertain in the Research

Research currently provides limited insight into several key areas. Subgroup findings are uncertain, as many trials did not specifically study or report outcomes for diarrhea caused by specific viruses or bacteria, or for patients with other underlying comorbid conditions. Furthermore, comparative evidence is not consistently available for a direct, high-quality assessment against all existing antidiarrheal agents.

Frequently Asked Questions (FAQ)

Common questions about Redotil (FAQ)


Q: Is Redotil a type of antibiotic or something else?

According to official regulatory documents, Redotil is classified as an antisecretory antidiarrheal agent, not an antibiotic. Its purpose is to treat the symptoms of acute watery diarrhea. It may be administered as a complementary treatment if an antibiotic or other causal treatment is required.


Q: How quickly does Redotil usually start working after taking it?

Official pharmacokinetic information indicates that the active substance is rapidly absorbed after being taken by mouth. The maximum effect of the enzyme inhibition, which provides relief, is typically achieved within one to two hours.


Q: How long does the effect of Redotil last in the body?

The duration of the therapeutic effect is defined by how long the active substance inhibits the relevant enzyme in the body. According to regulatory data, this inhibition lasts for approximately eight hours, which is consistent with the recommended administration frequency.


Q: Does Redotil cause drowsiness or affect driving?

Official product information states that the medicine has no or negligible influence on the ability to drive or use machinery. The medicine is described as acting primarily on the intestinal lining.


Q: Is it normal to feel a mild stomach upset after starting Redotil?

While the drug is used to treat a gastrointestinal condition, some side effects related to the digestive system have been reported. Regulatory documents note occurrences of nausea and vomiting. Referencing the official side effects section can provide the full safety profile and reported frequencies.


Q: Are there certain common foods or drinks that should be avoided while taking Redotil?

The official administration instructions advise that the capsule be taken preferably before the main meals. However, the product information does not list any common foods or drinks that are specifically prohibited.


Q: Can Redotil interact with pain relief medicines like ibuprofen or acetaminophen?

Product information notes a low potential for metabolic drug-drug interactions, as the active substance does not typically affect the major enzyme systems responsible for breaking down most other medicines. However, interaction studies with every specific over-the-counter medicine are not always detailed.


Q: Is Redotil okay to take if someone has high blood pressure?

General, uncomplicated high blood pressure is not listed as an official restriction. However, the medicine is contraindicated (restricted from use) in patients with a history of a specific severe swelling reaction (angioedema) that was previously linked to taking an Angiotensin-Converting Enzyme (ACE) inhibitor.


Q: Is Redotil available over the counter or is it only by prescription?

The legal classification of the medicine, determining if it is available over the counter or only by prescription, is regulated by the local health authority in each country. This classification may vary depending on the local regulations where the medicine is marketed.


Q: Is there any research looking at the use of Redotil in elderly patients?

Based on pharmacokinetic studies and regulatory documentation, officials have determined that dosage adjustment is not necessary when the medicine is prescribed to the elderly population. The standard administration schedule applies to this group.


Q: Does Redotil have any known interactions with herbal supplements or vitamins?

The official interactions section of the regulatory label focuses primarily on interactions with other medicinal products. It does not list specific warnings for commonly used herbal supplements or vitamins.


Q: What does the official drug information say about Redotil and alcohol consumption?

Official interaction studies regarding Redotil and alcohol consumption are typically not detailed in the regulatory label. However, the information confirms that the medicine has a negligible influence on the ability to drive or operate machinery.


Q: Can Redotil be taken when fasting?

While the label advises taking the adult dose before main meals, the regulatory documentation does not include specific warnings or restrictions related to taking the medicine during a period of fasting. The primary instruction is to take the dose three times daily.


Q: Does the efficacy of Redotil vary depending on what time of day it is taken?

To maintain a continuous therapeutic effect, the medicine is mandated to be taken three times daily, usually spaced throughout the day. Regulatory documents confirm there is no accumulation of the drug's active substance after these multiple doses administered every 8 hours.


Q: If Redotil is stopped suddenly, are there any known rebound effects?

The mechanism of action, which does not affect intestinal motility or basal secretory activity, is consistent with a low potential for rebound effects upon discontinuation, as noted in regulatory documents.


Q: Do food interactions impact how well Redotil is absorbed?

The official administration advice to take the adult dose 'preferably before the main meals' indicates that the timing relative to food intake is considered relevant. This timing is suggested to support optimal absorption of the active substance.


Q: What is the recommended period for review by a healthcare provider when using Redotil?

The maximum treatment duration is limited to seven days, and use should be discontinued once the patient passes two normal stools. These conditions limit the period of use; if symptoms worsen or persist, the treatment should be discussed with a healthcare provider.


Q: Does Redotil have any specific warnings for people with heart conditions?

General heart conditions are not listed as a contraindication. The only warning related to the vascular system involves a possible increased risk of a severe swelling reaction called angioedema, particularly when the medicine is used with ACE inhibitor medicines.


Q: Are there studies comparing different dosages of Redotil for effectiveness?

The standard dosage for Redotil is established based on the required clinical trials and regulatory approval processes. Studies relating to the bioavailability and pharmacokinetic linearity of different formulations have been conducted to confirm the intended dosage delivers the expected effect.


Q: Can Redotil interact with hormonal birth control pills?

The regulatory profile notes that the active substance does not inhibit or induce major CYP enzymes. This fact suggests a low likelihood of interaction with hormonal contraceptives, as major CYP enzyme induction is the primary mechanism by which these contraceptives lose effectiveness.


Q: Do studies suggest Redotil is generally well-tolerated?

Official assessment reports generally summarize that the medicine is well-tolerated and associated with a favorable safety profile. The medicine is reported to cause few side effects, and most of these are described as mild and temporary in nature.


Q: Can taking Redotil make existing medical conditions worse?

Official warnings advise caution for patients with pre-existing severe hepatic (liver) or renal (kidney) impairment. Use is also restricted for individuals with a history of ACE inhibitor-induced angioedema or specific hereditary sugar malabsorption disorders.


Q: Are there specific symptoms that mean Redotil might not be working?

The goal of treatment is for the patient to pass two normal stools, and the maximum duration is limited to seven days. If the desired outcome is not achieved, or if symptoms worsen (especially with fever or bloody stools), the treatment should be discussed with a healthcare provider, especially if symptoms worsen or persist.


Q: What is the difference between Redotil and Loperamide?

According to official documents, Redotil is an antisecretory agent that works by reducing the loss of water and electrolytes. This mechanism is distinct because it does not modify the intestinal transit time or motility, unlike treatments such as Loperamide, which primarily work by slowing bowel movement.


Q: Does Redotil help with all types of the condition it treats, or only specific kinds?

The medicine is indicated solely for the symptomatic treatment of acute watery diarrhea. It is specifically not recommended for use in cases of acute dysentery, which is characterized by the presence of bloody or purulent stools and fever.


Q: How does the way Redotil works compare to other common treatments?

The mechanism of action is distinguished from other agents by its pure intestinal antisecretory effect. It selectively decreases the hypersecretion of water and electrolytes without interfering with the intestinal transit time, which is a key factor cited in regulatory assessments.


Q: Does Redotil contain any common allergens like gluten or lactose?

The official product information confirms that the medicine contains lactose. Consequently, it is contraindicated (restricted from use) in patients who have specific hereditary problems such as lactose intolerance or related sugar malabsorption disorders. The product is not required to provide a specific statement regarding gluten content.


Q: If I am taking daily medication for a chronic disease, is Redotil usually compatible?

Generally, the medicine is compatible with most chronic disease treatments due to its low risk of metabolic interactions. However, a major regulatory prohibition exists against taking it if the patient has a history of angioedema while on an Angiotensin-Converting Enzyme (ACE) inhibitor.


Q: Why would a doctor prescribe Redotil instead of just recommending diet changes?

Redotil is not intended as a replacement for diet changes or supportive care. The official regulatory instruction specifies that it is prescribed as an adjunctive treatment, meaning it must be used alongside standard care like Oral Rehydration Solutions (ORS) and other supportive measures for acute diarrhea.


Q: Is it described anywhere that Redotil has effects on the central nervous system?

Official documents state that the active substance works exclusively in the periphery (the intestine) and has no effects on the central nervous system. The only noted exception in the nervous system disorders category is headache, which is listed as a common side effect.


Q: Can Redotil be taken by people with diabetes?

The official regulatory information notes that the medicine contains excipients (inactive ingredients) such as lactose and is contraindicated in specific sugar malabsorption disorders. Individuals with conditions like diabetes may wish to review the full excipient list with a healthcare provider.


Q: Why does the packaging for Redotil include a specific storage temperature?

The storage temperature limit (not exceeding 30 C) and environmental controls are mandates from regulatory agencies. These instructions are specified to ensure the medicine maintains its quality, intended potency, and stability throughout its labeled shelf life.


Q: Is the mechanism of action of Redotil similar to how electrolyte solutions work?

The mechanisms are different but complementary. Redotil works by decreasing the abnormal hypersecretion of water and electrolytes into the intestine. Oral Rehydration Solutions (ORS) work by replacing the water and electrolytes that have already been lost, which is why Redotil is prescribed as an adjunctive therapy to ORS.


Q: Why are there different types of granules (10mg and 30mg) for children?

The different strengths of granules are provided to facilitate the accurate, weight-based dosing specified for the pediatric formulation in regulatory guidelines.

How should Redotil be stored and disposed of?

Storage and Disposal Conditions for Redotil (Racecadotril)

The storage and disposal of Redotil must strictly follow the official instructions provided in regulatory labeling to maintain product stability and ensure public safety.


Official Storage Requirements

Requirement Condition
Temperature Limit Store at a temperature not exceeding 30 C.
Environmental Control Protect the medicine from both light and moisture.
Child Safety Keep out of the sight and reach of children (a mandatory labeled requirement).

Official Disposal Rules

  • Unused or expired product must be disposed of in accordance with local regulatory requirements.
  • To prevent environmental harm, the medicine should not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Redotil found in:

A-Z Index: